Status:

RECRUITING

The ctDNA-RECIST Trial Part One

Lead Sponsor:

Karen-Lise Garm Spindler

Collaborating Sponsors:

Vejle Hospital

Conditions:

Gastrointestinal Neoplasm

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

A study investigating if analysis of circulating tumor DNA (ctDNA) can guide palliative treatment in patients with gastrointestinal cancer.

Detailed Description

Background: Circulating tumor DNA, (ctDNA) has the potential to better monitor treatment efficacy compared to imaging, possibly sparing the patient for ineffective treatment and their associated toxi...

Eligibility Criteria

Inclusion

  • Incurable metastatic gastrointestinal cancer
  • Indication for first or second-line systemic treatment
  • Measurable disease according to RECIST v.1.1
  • CT of chest and abdomen less than 30 days old at time of treatment initiation
  • Age at least 18 years
  • ECOG performance status 0-2
  • Clinically eligible systemic palliative treatment at investigators decision.
  • Adequate bone marrow, liver and renal function allowing systemic chemotherapy
  • Anticonception for fertile women and for male patients with a fertile partner. Intrauterine device, vasectomy of a female subject's male partner or hormonal contraceptive are acceptable
  • Written and verbally informed consent

Exclusion

  • Incapacity, frailty, disability and comorbidity to a degree that according to the investigator is not compatible with combination chemotherapy
  • Other concurrent malignant tumor except non-melanoma skin cancer or carcinoma in situ cervicis uteri
  • Pregnant (positive pregnancy test) or breast-feeding women

Key Trial Info

Start Date :

January 15 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2030

Estimated Enrollment :

167 Patients enrolled

Trial Details

Trial ID

NCT06562348

Start Date

January 15 2025

End Date

September 1 2030

Last Update

May 1 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Aarhus University Hospital

Aarhus, Denmark, 8000

2

Department pf Oncology, Vejle Hospital

Vejle, Denmark, 7100

The ctDNA-RECIST Trial Part One | DecenTrialz